Trial
NCT02048969
Treatment of Hepatic Encephalopathy With Flumazenil and Change in Cortical GABA Levels in MRS
Phase IWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
Yale University
Collaborators
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Condition
Hepatic Encephalopathy
Intervention
Flumazenil
Why stopped
No subjects were able to be recruited for the study.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-07-07